Subtotal $0.00
Shop Now
“HGH peptides” is a marketing term for growth hormone secretagogues: peptides that signal the pituitary gland to release more of the body’s own growth hormone. They are not human growth hormone (HGH) itself. HGH, or somatropin, is a 191-amino-acid protein that is an FDA-approved prescription drug for specific conditions, and distributing it for other uses is a federal crime. Among the secretagogue peptides, only tesamorelin is an approved therapy, for one narrow use, and sermorelin’s approval was withdrawn years ago. The rest are unapproved, with little human evidence beyond hormone-level studies. This guide compares the two and explains the legal and safety issues.
Key Takeaways
- HGH (somatropin) is a prescription protein for growth hormone deficiency and other labeled conditions.
- HGH peptides are secretagogues that make the pituitary release growth hormone; they are not HGH.
- Tesamorelin is the only secretagogue peptide approved as a therapy in the U.S., for HIV-related abdominal fat.
- Raising growth hormone raises IGF-1, and labels warn about related risks such as fluid retention, glucose intolerance and tumors.
- WADA 2026 bans growth hormone and all of these secretagogues at all times.
What is human growth hormone?
Growth hormone is made by the pituitary gland at the base of the brain. The medicine version, somatropin, matches the natural hormone: according to the Genotropin label it is a protein of 191 amino acids with a molecular weight of 22,124 daltons. It is made with recombinant DNA technology.
Somatropin products are FDA-approved for specific diagnosed conditions. The Genotropin label covers children with growth failure from growth hormone deficiency, Prader-Willi syndrome, being born small for gestational age, Turner syndrome and idiopathic short stature, plus adults with growth hormone deficiency. Another brand, Serostim, is approved for wasting in people with HIV.
Federal law restricts growth hormone more tightly than most prescription drugs. Under 21 U.S.C. 333(e), knowingly distributing it, or possessing it to distribute, for any human use other than an FDA-authorized use prescribed by a physician can bring up to 5 years in prison, or up to 10 years if someone under 18 is involved. The law defines growth hormone as somatrem, somatropin or an analogue of either.
What are HGH peptides?
Growth hormone release is controlled by two signals that act on the pituitary. HGH peptides copy one or the other:
- GHRH analogs copy growth hormone-releasing hormone from the hypothalamus. They include sermorelin, tesamorelin and CJC-1295.
- Ghrelin mimetics act on the ghrelin receptor, also called the growth hormone secretagogue receptor. They include ipamorelin, GHRP-2 and GHRP-6. Because the ghrelin receptor also affects appetite and stress hormones, some of these raise hunger or cortisol.
Two related compounds often appear in the same conversations. AOD-9604 is a fragment of growth hormone rather than a secretagogue, and IGF-1 LR3 is a modified copy of IGF-1, the hormone growth hormone triggers. Neither is approved.
Peptides or HGH: how they differ
| Feature | HGH (somatropin) | HGH peptides (secretagogues) |
|---|---|---|
| What it is | The growth hormone protein itself | Signals that make the pituitary release growth hormone |
| Size | 191 amino acids | Usually 5 to 44 amino acids |
| Depends on a working pituitary? | No | Yes |
| FDA status | Approved Rx for specific conditions | Only tesamorelin approved as a therapy |
| Special federal law | 21 U.S.C. 333(e) distribution limits | General FDA drug rules |
| WADA 2026 | S2, prohibited at all times | S2, prohibited at all times |
Regulatory status of HGH peptides
| Compound | Type | FDA status | Compounding note (2026) |
|---|---|---|---|
| Tesamorelin | GHRH analog | Approved Rx (Egrifta) for HIV lipodystrophy abdominal fat | Compounded versions are not FDA-approved |
| Sermorelin | GHRH analog | Formerly approved (Geref, withdrawn 2009) | Not in Category 2; compounded versions not FDA-approved |
| CJC-1295 | GHRH analog | Not approved | Out of Category 2; not eligible for 503A compounding |
| Ipamorelin | Ghrelin mimetic | Not approved | Advisory committee voted 12-0 against in 2024 |
| GHRP-2, GHRP-6 | GHRPs | Not approved | Category 3, nominated without adequate support |
| Macimorelin (Macrilen) | Oral ghrelin-receptor agonist | Approved 2017 as a diagnostic test | Used to test for adult GH deficiency, not as a therapy |
None of the unapproved peptides was among those the FDA’s advisory committee reviewed in July 2026, and none is on the list of bulk substances pharmacies may use for compounding. Products sold online with research labels are not approved medicines. In an August 2026 warning letter to one seller whose products included tesamorelin, the FDA rejected such labels and said the products were intended to be drugs for human use. Read more in are peptides legal in the U.S..
What the evidence shows
For the unapproved HGH peptides, human research mostly measured hormone levels. Two 2006 trials of CJC-1295 in healthy adults found growth hormone rose 2- to 10-fold and IGF-1 1.5- to 3-fold, but they did not test health outcomes. Ipamorelin’s main trial, in 117 adults after bowel surgery, did not reach statistical significance. GHRP-2 has been used mainly to test pituitary function. Raising hormone levels on a blood test does not show that a compound improves muscle, fat, energy or aging.
Even growth hormone itself has a weak record for those goals. A 2008 review of trials in 303 young, fit adults found about 2.1 kg more lean body mass but no clear gain in strength or exercise capacity, with more swelling and fatigue. A 2007 review in 220 healthy older adults found small body-composition changes and more side effects, and concluded growth hormone could not be recommended as an anti-aging therapy.
Secretagogues also depend on a pituitary gland that can still make growth hormone, so their effect varies from person to person and is limited by the body’s own feedback controls. That is one reason results from somatropin studies cannot simply be applied to the peptides.
Safety concerns, including IGF-1 elevation
Growth hormone works largely through IGF-1, so anything that raises growth hormone tends to raise IGF-1 too. The tesamorelin label warns that it raises IGF-1 and that the long-term effects are unknown, and it lists fluid retention, glucose intolerance and tumor risk. Somatropin labels warn about tumors, impaired glucose tolerance and diabetes, raised pressure inside the skull, fluid retention and pancreatitis, and they rule out use in people with active cancer or acute critical illness.
For unapproved peptides the FDA has named additional concerns: possible immune reactions and impurities, serious adverse events including increased heart rate for CJC-1295, and serious adverse events including death in a published study of intravenous ipamorelin. Research-labeled products are not checked for identity, purity or sterility.
Sport and the WADA 2026 list
WADA’s 2026 Prohibited List bans growth hormone and its analogues and fragments, GHRH analogs such as CJC-1295, sermorelin and tesamorelin, growth hormone secretagogues such as ipamorelin and macimorelin, and GHRPs including GHRP-2 and GHRP-6, all under class S2. They are prohibited at all times, in and out of competition.
If you have symptoms that might point to a growth hormone problem, a licensed healthcare provider can arrange proper testing. For more compound profiles, see the Peptide Guide.
Frequently Asked Questions
What are HGH peptides?
They are growth hormone secretagogues, peptides that signal the pituitary gland to release growth hormone. Examples include sermorelin, CJC-1295, ipamorelin and GHRP-2. They are not HGH.
Peptides or HGH: which is legal?
Somatropin is legal only as a prescription for approved conditions. Of the peptides, only tesamorelin is an approved therapy, for one narrow use; most others are unapproved drugs.
Are HGH peptides safer than HGH?
That has not been shown. Most have little human safety data, and the FDA has cited immune reactions, impurities and serious adverse events for some of them.
Do HGH peptides raise IGF-1?
Yes, raising growth hormone generally raises IGF-1. The tesamorelin label says the long-term effects of higher IGF-1 are unknown.
Is sermorelin FDA-approved?
Not anymore. It was sold as Geref until the approvals were withdrawn in 2009 at the maker’s request, and no approved sermorelin product is marketed now.
Are HGH peptides banned in sport?
Yes. WADA 2026 lists GHRH analogs, growth hormone secretagogues and GHRPs under S2, prohibited at all times.
This article is general information, not medical or legal advice. Peptide Labs does not sell prescription, investigational or unapproved peptides, including any compound named here. Ask a licensed healthcare provider or pharmacist how this information applies to you.
Last reviewed September 2026.
Related guides: Peptides for Muscle Growth: What the Evidence and the FDA Say, Are Peptides Safe? Side Effects and Risks by Type of Peptide, Tesamorelin vs Sermorelin: FDA Status, Mechanism and What the Evidence Shows.